DiagnosTear Achieves Major Scientific Milestone with Publication of TeaRx(TM) Clinical Study in Current Eye Research Journal

Publication in a leading peer-reviewed ophthalmology journal further validates TeaRx™ as a novel point-of-care platform for diagnosis, patient stratification, and prediction of responsiveness to therapy in Dry Eye Disease https://pubmed.ncbi.nlm.nih.gov/42206882/ Vancouver, British Columbia--(Newsfile Corp. - June 5, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) ("DiagnosTear" or the "Company"), a leader in developing innovative point-of-care diagnostic solutions for ocular diseases, is pleased to announce that its clinical manuscript entitled "Clinical Evaluation of TeaRx™: A Point-of-Care Multi-Parameter Tear Film Test for Diagnosis, Stratification, and Prediction of Responsiveness to Cyclosporine A Therapy in Dry Eye Disease" has been published (as an open access manuscript) in the peer-reviewed journal Current Eye Research, a well-established international ophthalmology journal with an impact factor of approximately 2.1. The manuscript can be accessed and viewed at https://www.tandfonline.com/doi/10.1080/02713683.2026.2678293 The study was conducted in collaboration with Prof.